Lin, Yu-Ling <br/><br/>
In vivo amelioration of endogenous antitumor autoantibodies via low-dose P4N through the LTA4H/activin A/BAFF pathway.  [electronic resource] 

 -  Proceedings of the National Academy of Sciences of the United States of America  11 2016 
 - E7798-E7807 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1091-6490 
<br/><br/><label>Standard No.: </label>10.1073/pnas.1604752113  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Activins--genetics<br/>Animals<br/>Antibodies, Neoplasm--blood<br/>Antineoplastic Agents--administration & dosage<br/>Autoantibodies--blood<br/>B-Cell Activating Factor--genetics<br/>B-Lymphocytes--drug effects<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Colorectal Neoplasms--drug therapy<br/>Dose-Response Relationship, Drug<br/>Drug Screening Assays, Antitumor<br/>Endoplasmic Reticulum Chaperone BiP<br/>Epoxide Hydrolases--genetics<br/>Female<br/>Gene Expression<br/>Immunity, Humoral--drug effects<br/>Immunologic Factors--administration & dosage<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Neoplasm Transplantation<br/>Phenyl Ethers--administration & dosage<br/>Piperidines--administration & dosage<br/>Signal Transduction<br/>Tumor Burden